Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$247.91
-0.6%		$255.74
$186.05
▼
$282.15
$15.46B0.39503,223 shs314,792 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$76.60
-2.6%		$80.08
$48.78
▼
$93.42
$14.97B0.962.10 million shs1.92 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$25.07
-3.9%		$24.37
$11.92
▼
$27.31
$4.68B1.071.76 million shs1.19 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$54.45
-1.5%		$54.57
$33.76
▼
$57.57
$13.49B0.442.68 million shs1.49 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%-2.12%-1.26%+10.62%+28.44%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-6.01%-6.74%+15.61%+54.47%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.00%-3.95%-2.57%+29.69%+83.80%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+0.68%-2.72%+7.86%+41.39%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$247.91
-0.6%		$255.74
$186.05
▼
$282.15
$15.46B0.39503,223 shs314,792 shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$76.60
-2.6%		$80.08
$48.78
▼
$93.42
$14.97B0.962.10 million shs1.92 million shs
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
$25.07
-3.9%		$24.37
$11.92
▼
$27.31
$4.68B1.071.76 million shs1.19 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$54.45
-1.5%		$54.57
$33.76
▼
$57.57
$13.49B0.442.68 million shs1.49 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.00%-2.12%-1.26%+10.62%+28.44%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-6.01%-6.74%+15.61%+54.47%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.00%-3.95%-2.57%+29.69%+83.80%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%+0.68%-2.72%+7.86%+41.39%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
3.05
Buy$302.6822.09% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$100.7931.58% Upside
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
2.87
Moderate Buy$34.4237.28% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.30
Hold$50.07-8.05% Downside

Current Analyst Ratings Breakdown

Latest DYN, BBIO, ASND, and EXEL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/27/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$345.00
8/27/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$345.00
8/18/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$54.00
8/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$319.00
8/18/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$319.00
8/18/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
BMO Capital Markets logo
BMO Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageMarket Perform$54.00
8/17/2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$50.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$280.00 ➝ $290.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$325.00 ➝ $341.00
8/14/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$345.00 ➝ $329.00
8/13/2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$333.00
(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$814.57M18.99N/AN/A$26.78 per share9.26
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$713.07M21.00N/AN/A($12.81) per share-5.98
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/A$3.76 per shareN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.44B5.54$3.03 per share17.99$7.44 per share7.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$258M$12.8919.2324.30N/A70.99%32.54%7.71%11/11/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$446.21M-$3.33N/AN/AN/AN/A-64.30%-50.33%11/4/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1817.1214.681.6235.33%42.17%31.76%11/3/2026 (Estimated)

Latest DYN, BBIO, ASND, and EXEL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$1.71$1.0270-$0.6830$3.23$376.75 million$387.22 million
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
7/30/2026Q2 2026
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
-$0.7488-$1.08-$0.3312-$1.08N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
0.27
2.99
2.32
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
0.28
12.02
12.02
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
96.68%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
9.46%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,18962.38 million37.43 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
400195.49 million167.67 millionOptionable
Dyne Therapeutics, Inc. stock logo
DYN
Dyne Therapeutics
100186.75 million169.08 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable

Recent News About These Companies

Legal & General Group Plc Invests $19.56 Million in Exelixis, Inc. $EXEL
August 30 at 4:57 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-1956-million-in-exelixis-inc-exel-2026-08-30/
The Manufacturers Life Insurance Company Takes $9.88 Million Position in Exelixis, Inc. $EXEL
August 30 at 4:56 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-takes-988-million-position-in-exelixis-inc-exel-2026-08-30/
FY2026 EPS Estimates for Exelixis Lifted by Zacks Research
August 30 at 1:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30991275
Empowered Funds LLC Cuts Position in Exelixis, Inc. $EXEL
August 29 at 4:50 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-empowered-funds-llc-cuts-position-in-exelixis-inc-exel-2026-08-29/
Zacks Research Has Pessimistic View of Exelixis Q4 Earnings
August 29 at 1:29 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30989282
Strong Sales, Earnings Send Exelixis Shares Higher
August 28 at 11:23 AM  |  fxempire.comF
Analysts Offer Predictions for Exelixis FY2026 Earnings
August 28 at 7:26 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-analysts-offer-predictions-for-exelixis-fy2026-earnings-2026-08-28/
Jupiter Topco LLC Purchases Shares of 1,236,393 Exelixis, Inc. $EXEL
August 28 at 5:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-jupiter-topco-llc-purchases-shares-of-1236393-exelixis-inc-exel-2026-08-28/
Exelixis, Inc. (NASDAQ:EXEL) Given Average Rating of "Hold" by Brokerages
August 28 at 4:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-exelixis-inc-nasdaq-exel-given-average-rating-of-hold-by-brokerages-2026-08-28/
Canada Pension Plan Investment Board Invests $35.46 Million in Exelixis, Inc. $EXEL
August 28 at 3:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-canada-pension-plan-investment-board-invests-3546-million-in-exelixis-inc-exel-2026-08-28/
Investors Purchase High Volume of Put Options on Exelixis (NASDAQ:EXEL)
August 27 at 2:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-investors-purchase-high-volume-of-put-options-on-exelixis-nasdaq-exel-2026-08-27/
What is Zacks Research's Forecast for Exelixis Q4 Earnings?
August 27 at 6:26 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-what-is-zacks-researchs-forecast-for-exelixis-q4-earnings-2026-08-27/
Strategic Global Advisors LLC Makes New Investment in Exelixis, Inc. $EXEL
August 27 at 5:44 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-strategic-global-advisors-llc-makes-new-investment-in-exelixis-inc-exel-2026-08-27/
Man Group plc Takes $24.85 Million Position in Exelixis, Inc. $EXEL
August 27 at 5:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-man-group-plc-takes-2485-million-position-in-exelixis-inc-exel-2026-08-27/
OMERS ADMINISTRATION Corp Takes Position in Exelixis, Inc. $EXEL
August 27 at 5:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-omers-administration-corp-takes-position-in-exelixis-inc-exel-2026-08-27/
Caisse de depot et placement du Quebec Invests $113.95 Million in Exelixis, Inc. $EXEL
August 27 at 4:16 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-caisse-de-depot-et-placement-du-quebec-invests-11395-million-in-exelixis-inc-exel-2026-08-27/
Deutsche Bank AG Takes Position in Exelixis, Inc. $EXEL
August 27 at 3:35 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-deutsche-bank-ag-takes-position-in-exelixis-inc-exel-2026-08-27/
Sanctuary Advisors LLC Makes New Investment in Exelixis, Inc. $EXEL
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-sanctuary-advisors-llc-makes-new-investment-in-exelixis-inc-exel-2026-08-26/
L2 Asset Management LLC Takes Position in Exelixis, Inc. $EXEL
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-l2-asset-management-llc-takes-position-in-exelixis-inc-exel-2026-08-25/
78,937 Shares in Exelixis, Inc. $EXEL Acquired by Commerce Bank
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-78937-shares-in-exelixis-inc-exel-acquired-by-commerce-bank-2026-08-25/
Bank of New York Mellon Corp Invests $107.80 Million in Exelixis, Inc. $EXEL
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-invests-10780-million-in-exelixis-inc-exel-2026-08-25/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Laboratory with a cryogenic quantum processor chamber, optical laser setup on a table, and data monitors displaying waveforms.
Quantum Earnings Week: Winners and Losers Are Finally Emerging
By Nathan Reiff | August 8, 2026
SpaceX logo beside a rocket on a launch pad at sunset, with a colorful sky in the background.
SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
By Jeffrey Neal Johnson | August 3, 2026
Autonomous mobile robots carrying storage bins move through an automated factory production line with illuminated blue accents.
3 Robotics Stocks Under $10: Value, Momentum, or Bet?
By Chris Markoch | August 17, 2026
Medical imaging scanner with exposed internal components being assembled in a manufacturing facility with computer workstations.
Inside Teledyne's Bold Bet on the Future of Medical Imaging
By Jeffrey Neal Johnson | August 14, 2026
A rubber stamp reading "Dividends" rests beside a stamped document, stacked coins, and US currency.
3 Closed-End Funds to Maximize Dividend Payments
By Nathan Reiff | August 23, 2026
Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$247.91 -1.45 (-0.58%)
As of 08/28/2026 04:00 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$76.60 -2.08 (-2.64%)
As of 08/28/2026 04:00 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Dyne Therapeutics stock logo

Dyne Therapeutics NASDAQ:DYN

$25.07 -1.02 (-3.91%)
As of 08/28/2026 04:00 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$54.45 -0.81 (-1.47%)
As of 08/28/2026 04:00 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas